|
|
|
Genmab Achieves USD 40M Milestone in Collaboration with AbbVie
“We are very pleased that the first Phase 3 study of epcoritamab has been activated at multiple clinical sites and the first cancer patient has been dosed. We look forward to continued rapid progress in this exciting and rapidly broadening development program,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
|
|
ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI7386 Combination for mCRPC Patients
“We are delighted to collaborate with Janssen to explore the potential clinical role of EPI-7386 in combination with the antiandrogens apalutamide and abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer,” said Dr. David. R. Parkinson, Chief Executive Officer, ESSA Pharma Inc. “EPI-7386 binds to the androgen receptor targeting the opposite end of the androgen receptor from current therapies. In preclinical models, we have seen that combining EPI-7386 with current antiandrogens can lead to deeper and broader inhibition of androgen biology. We look forward to investigating these combination therapies and their potential to improve the treatment of prostate cancer.”
|
|
|
Landos Biopharma plans an IPO of $100 M for its AI based prediction of immune-metabolic functions
Landos Biopharma Inc. (Landos; Blacksburg, VA) owns an AI based- LANCE platform that makes predictions to identify novel expression patterns tied to regulatory functions in immune cells, modulating their inflammatory activity. Landos has identified 7 novel immune metabolic targets across 14 indications, including ulcerative colitis, Crohn’s disease, lupus, rheumatoid arthritis, non-alcoholic steatohepatitis, multiple sclerosis, Alzheimer’s disease, asthma, psoriasis, atopic dermatitis, chronic obstructive pulmonary disease, eosinophilic esophagitis, diabetic nephropathy and type 1 diabetes. Its lead molecule BT-11, has completed phase II clinical trials for mild to moderate ulcerative colitis. BT-11 targets Lanthionine Synthetase C-Like 2 (LANCL2), a membrane receptor that modulates immunological mechanisms associated with autoimmune diseases. Landos now plans to expand BT-11 to eosinophilic esophagitis, psoriasis and atopic dermatitis.
On January 13th 2021, Landos filed an IPO of $100 million. It has venture backing from Perspective Advisors and RTW Investments.
|
|
KSQ Therapeutics enters strategic collaboration with Takeda, receiving $100 million to address novel CRISPR-based immuno-oncology therapies
KSQ Therapeutics’ (Cambridge, MA) proprietary CRISPRomics® discovery platform for systematic screening of whole genome to optimally target T cells and NK cells, has interested Takeda (HQ: Tokyo, Japan) to enter into a broad strategic collaboration for research and product development aimed at turning cold tumours hot. The deal, which involves an initial upfront cash payment of $100 million to KSQ, has the potential for further commercial and developmental milestone payments to the tune of $400 million per therapeutic program. In return Takeda will enjoy an exclusive, global license (royalties included) to develop and manufacture all products arising from KSQ’s discovery pipeline that modulate T cell and NK cell targets. While the T cell targets are already validated by KSQ, Takeda will collaborate over NK cell target discovery and validation. The announcement was made on 13th January 2021.
Further, Takeda will take over all commercial development and distribution of promising therapeutics pipelines (including investigational new drugs enabling activities) with KSQ enjoying tiered royalties on all approved products in the US, and complete royalties on ex- US sales.
KSQ’s platform screens all the genes in the T & NK cell genomes to identify potent target specific killing activity across 600 cancer models including PD-1 resistant tumours. For further explanation on the platform, click here.
“KSQ’s CRISPRomics discovery platform is a powerful technology to help us identify novel targets in line with our immuno-oncology strategy…The T-cell and NK-cell target discovery approach complements our portfolio aimed at turning cold tumors hot and redirecting the innate immune system to elicit a sustained and durable immune response against tumors. Working alongside KSQ will facilitate smart drug discovery and development of what we hope will be transformative new therapies for patients with intractable forms of cancer.”- said Loïc Vincent, Head, Oncology Drug Discovery Unit and Immunology Unit at Takeda.
|
|
Click here for more on mergers, acquisition and business news
|
|
|
Disclaimer
The editors take care to share authentic information. In case of any discrepancies please write to medness.newsletter@gmail.com
The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Medness. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for Medness. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
|
|
|
|
|
|
|